Clinical Trial

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-27.
Trial Details
NCT Number NCT07619339
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Summit Therapeutics
Conditions Non-Small Cell Lung Cancer
Enrollment 16 participants
Start Date 2026-05-27
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-11